The Native Antigen Company human coronavirus antigens and antibodies

Thursday, 12 May, 2022 | Supplied by: BioNovus Life Sciences


The Native Antigen Company develops and manufactures high-quality recombinant antigens and antibodies as well as offering a range of services for the diagnostic and biopharmaceutical industries. The company’s VirtuE mammalian expression system has been developed for the purpose of producing native-like proteins, which are being widely adopted by in vitro diagnostic, vaccine and academic groups in cutting-edge R&D, where correct folding and glycosylation are vital.

There are six different coronaviruses that can infect humans and cause illness. These comprise the four common coronaviruses — 229E and NL63 (alpha coronaviruses), and OC43 and HKU1 (beta coronaviruses) — and two other coronaviruses, MERS-CoV and SARS-CoV, both of which can cause severe illness and remain a significant public health concern. Following the declaration of SARS-CoV-2 pandemic by the WHO in March 2020, Native Antigen has rapidly expanded its range of SARS-CoV-2 recombinant antigens and antibodies.

To support the investigation of SARS-CoV-2 variants, the company offers a growing range of mutant Spike antigens. Expressed through the VirtuE mammalian expression system, the antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications.

Online: www.bionovuslifesciences.com.au
Phone: 02 9484 0931
Related Products

Aviva Systems Biology AvivaBlot ECL Reagents

AvivaBlot ECL Reagents are stabilised, pre-mixed formulations that allow for room-temperature...

Absolute Antibody Prometheus antibody humanisation service

Absolute Antibody has expanded its Prometheus antibody humanisation service to offer humanisation...

Dolomite Bio nadAROSE and nadia3D hydrogel reagent kits

Dolomite Bio is launching two hydrogel-focused reagent kits, enabling high-throughput...


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd